Drug-induced liver injury: A clinical update

Current Opinion in Gastroenterology

Volumn 26, Issue 3, 2010, Pages 222-226

  Ghabril, Marwan ^a   Chalasani, Naga ^a   Björnsson, Einar ^b  

^a INDIANA UNIVERSITY   (United States)

^b LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

Diagnosis; Drug induced liver injury; Hepatotoxicity; Natural history

Indexed keywords

ACETYLCYSTEINE; FIBRIC ACID DERIVATIVE; FLUCLOXACILLIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEUKOCYTE ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; QUINOLONE DERIVATIVE; TELITHROMYCIN;

CLINICAL TRIAL; DIET SUPPLEMENTATION; DOSE RESPONSE; GENOTYPE; HUMAN; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; LIVER TRANSPLANTATION; REVIEW; RISK FACTOR; TOXIC HEPATITIS;

DRUG-INDUCED LIVER INJURY; HUMANS;

EID: 77951288290     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3283383c7c     Document Type: Review

References (27)

1. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137:947-954. (Pubitemid 35440240)
2. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354:731-739.
3. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135:1924-1934; 34e1-4
4. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129:512-521.
5. Takikawa H, Murata Y, Horiike N, et al. Drug-induced liver injury in Japan: an analysis of 1676 cases between 1997 and 2006. Hepatol Res 2009; 39:427-431.
6. Tameda TAY, Watanabe A. A national survey of drug induced liver injury. Tokyo: Shinko-Igaku; 2001.
7. Onji M, Fujioka S, Takeuchi Y, et al. Clinical characteristics of drug-induced liver injury in the elderly. Hepatol Res 2009; 39:546-552.
8. Lucena MI, Andrade RJ, Kaplowitz N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 2009; 49:2001-2009.
9. Bjornsson E. The natural history of drug-induced liver injury. Semin Liver Dis 2009; 29:357-363.
10. Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Semin Liver Dis 2009; 29:400-411.
11. Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B*57015701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41:816-819.
12. Bissell DM, Gores GJ, Laskin DL, Hoofnagle JH. Drug-induced liver injury: mechanisms and test systems. Hepatology 2001; 33:1009-1013. (Pubitemid 32246655)
13. Rochon J, Protiva P, Seeff LB, et al. Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology 2008; 48:1175-1183.
14. Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed Philadelphia: Lippincott Williams & Wilkins; 1999.
15. de Abajo FJ, Montero D, Madurga M, Garcia Rodriguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004; 58:71-80. (Pubitemid 38901470)
16. Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 2007; 47:513-539. (Pubitemid 46272137)
17. Lammert C, Einarsson S, Saha C, et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008; 47:2003-2009. (Pubitemid 351945567)
18. Bjornsson E, Olsson R. Outcome and prognostic markers in severe druginduced liver disease. Hepatology 2005; 42:481-489. (Pubitemid 41061102)
19. Russo MW, Galanko JA, Shrestha R, et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004; 10:1018-1023. (Pubitemid 39232756)
20. Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2010; 51:615-620.
21. Suzuki A, Yuen N, Walsh J, et al. Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury. Clin Gastroenterol Hepatol 2009; 7:882-888.
22. Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut 1999; 44:731-735.
23. Andrade RJ, Lucena MI, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology 2006; 44:1581-1588. (Pubitemid 44953663)
24. Bjornsson E, Davidsdottir L. The long-term follow-up after idiosyncratic druginduced liver injury with jaundice. J Hepatol 2009; 50:511-517.
25. Brinker AD, Wassel RT, Lyndly J, et al. Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology 2009; 49:250-257.
26. Coleman CI, Spencer JV, Chung JO, Reddy P. Possible gatifloxacin-induced fulminant hepatic failure. Ann Pharmacother 2002; 36:1162-1167. (Pubitemid 34755791)
27. Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage nonacetaminophen acute liver failure. Gastroenterology 2009; 137:856-864; 64e1..